Communicable Diseases in India

Overview

Communicable diseases — infections that spread from person to person, through vectors, or via contaminated environments — have shaped India's demographic and social history more profoundly than perhaps any other factor. Smallpox killed millions annually until its eradication in 1975. Cholera and plague epidemics devastated cities. Malaria determined settlement patterns in large parts of the country. Tuberculosis (TB) remains the world's largest infectious killer, and India bears the highest burden. The HIV/AIDS epidemic, which arrived in the 1980s, transformed public health policy and civil liberties. And COVID-19, in 2020–2022, exposed both the strengths and the catastrophic weaknesses of India's health system.

India's battle against communicable diseases is a story of remarkable achievements and persistent failures. The country eradicated smallpox in 1975 and polio in 2014 — achievements that required massive mobilization, international cooperation, and sustained political commitment. Yet it continues to struggle with diseases that are preventable and treatable: TB, malaria, Japanese encephalitis, and a host of neglected tropical diseases. The reasons are structural: poverty, malnutrition, inadequate sanitation, weak primary health care, and the social determinants of health that make some populations far more vulnerable than others.

This module examines the major communicable diseases affecting India, the national programs designed to combat them, the successes and failures of those programs, and the systemic challenges that continue to undermine public health. It also covers the remarkable story of disease eradication — from smallpox to polio — as a demonstration of what is possible when resources, will, and organization align.

Tuberculosis: India's Silent Epidemic

India has the highest TB burden in the world, accounting for approximately 28% of global cases. An estimated 2.7 million people develop TB in India every year, and over 400,000 die from it — making TB one of the leading causes of death in the country. Despite being curable with a six-month course of antibiotics, TB persists because of delayed diagnosis, incomplete treatment, drug resistance, and the social conditions that fuel transmission.

The Disease and Its Burden

• Pulmonary and extrapulmonary TB: TB primarily affects the lungs (pulmonary TB) but can affect any part of the body — the brain, spine, kidneys, and lymph nodes. Extrapulmonary TB is harder to diagnose and often requires longer treatment. The disease spreads through airborne droplets when an infected person coughs, making crowded and poorly ventilated environments — prisons, slums, public transport — high-risk settings.
• Social determinants: TB is a disease of poverty. Malnutrition, overcrowding, poor ventilation, and occupational exposure (silica dust in mining, for example) increase vulnerability. India has the highest number of undernourished people in the world, and malnutrition is the single most important risk factor for TB. The disease, in turn, pushes families deeper into poverty through lost wages and catastrophic health expenditure.
• Stigma and gender: TB carries significant social stigma, particularly for women. Women with TB face rejection by families, difficulty in marriage, and loss of employment. The stigma discourages people from seeking diagnosis and completing treatment, fueling transmission and drug resistance.

The Revised National Tuberculosis Control Program (RNTCP) / National TB Elimination Program (NTEP)

• DOTS strategy: Since 1997, India's TB program has used the Directly Observed Treatment, Short-course (DOTS) strategy, in which patients take medication under the supervision of a health worker to ensure compliance. DOTS achieved high cure rates (over 85%) but struggled to reach all patients, particularly in the private sector where most Indians seek care.
• Nikshay and digital tracking: The Nikshay platform (launched 2012) is a web-based system for tracking TB patients, monitoring drug supplies, and reporting outcomes. It represents a significant improvement in data collection but faces challenges with private sector reporting and data quality.
• Drug-resistant TB (DR-TB): Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are growing threats, caused by incomplete or incorrect treatment. India has an estimated 130,000 MDR-TB cases annually. Treatment for DR-TB is far more expensive, lasts up to two years, and involves toxic drugs with severe side effects. The bedaquiline and delamanid regimens, newer drugs for DR-TB, have been rolled out but access remains limited.
• Private sector engagement: An estimated 50–70% of TB patients in India first seek care in the private sector — from general practitioners to unqualified practitioners. The private sector has historically operated outside the national program, leading to irrational drug regimens, poor monitoring, and generation of drug resistance. The NTEP has attempted to engage the private sector through incentives, free drugs, and mandatory reporting, but implementation is uneven.
• TB elimination target: India has committed to eliminating TB by 2025 — five years ahead of the global Sustainable Development Goal target. This is an ambitious goal that would require diagnosing and treating every case, addressing social determinants, and achieving near-perfect treatment completion rates. Progress is being made, but elimination by 2025 appears unlikely.

Malaria: Progress and Persistent Challenges

Malaria has been endemic in India for millennia, shaping settlement patterns, agricultural practices, and demographic trends. The disease is transmitted by female Anopheles mosquitoes and caused by Plasmodium parasites. India has made significant progress in reducing malaria incidence — from approximately 20 million cases in the 1940s to under 200,000 confirmed cases in recent years — but elimination remains elusive.

The National Vector Borne Disease Control Program (NVBDCP)

• Vector control: The primary malaria control strategies in India are insecticide-treated bed nets (ITNs), indoor residual spraying (IRS) with insecticides, and larval source management (draining stagnant water, larviciding). The government has distributed millions of free ITNs in endemic areas. However, mosquito resistance to insecticides — particularly pyrethroids — is a growing problem.
• Diagnosis and treatment: Rapid diagnostic tests (RDTs) and microscopy are used for diagnosis. Artemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated falciparum malaria. The government provides free diagnosis and treatment through public health facilities.
• Regional variation: Malaria burden is concentrated in specific regions: Odisha, Chhattisgarh, Jharkhand, Madhya Pradesh, and the Northeastern states account for the majority of cases. Tribal and forested areas are particularly high-risk due to mosquito breeding sites and limited health infrastructure.
• Malaria elimination goal: India has pledged to eliminate malaria by 2030. The "National Framework for Malaria Elimination" (2016) outlines a phased approach, with elimination targeted in low-transmission states first. Progress has been substantial, but challenges include drug resistance (emerging artemisinin resistance in Southeast Asia threatens India), insecticide resistance, climate change (expanding mosquito habitats), and the difficult terrain of remaining endemic areas.

HIV/AIDS: From Crisis to Chronic Management

India's HIV epidemic, which began in the mid-1980s, was once projected to become the world's largest. Through a combination of targeted interventions, antiretroviral therapy (ART) scale-up, and behavior change programs, India has managed to stabilize the epidemic at an estimated 2.4 million people living with HIV — far below early projections of 20–25 million.

The National AIDS Control Program (NACP)

• Targeted interventions: The NACP focused its prevention efforts on "high-risk groups" — female sex workers, men who have sex with men (MSM), transgender persons (hijras), injecting drug users, and truckers/migrants. Targeted interventions provided condoms, needle exchange programs, opioid substitution therapy, and STI treatment. These programs were remarkably successful in reducing transmission among high-risk groups.
• ART scale-up: India launched free ART in 2004, initially at eight centers, now expanded to over 600 ART centers and 1,200 link ART centers across the country. Over 1.7 million people are currently on ART. The "test and treat" policy (initiating ART immediately upon diagnosis, regardless of CD4 count) was adopted in 2017, aligning with WHO guidelines.
• Legal and social challenges: Section 377 of the Indian Penal Code, which criminalized homosexual acts, was struck down by the Supreme Court in 2018 — a landmark victory for LGBTQ+ rights and HIV prevention. However, stigma against people living with HIV remains widespread, affecting employment, housing, and healthcare access. The HIV and AIDS (Prevention and Control) Act, 2017 prohibits discrimination and guarantees treatment, but implementation is weak.
• Mother-to-child transmission: The program for Prevention of Parent to Child Transmission (PPTCT) provides HIV testing for pregnant women, ART for HIV-positive mothers, and safe delivery practices. Mother-to-child transmission rates have declined significantly, but gaps remain in rural and tribal areas.

COVID-19: A Stress Test for Public Health

The COVID-19 pandemic was the most significant public health crisis in India since the 1918 influenza pandemic. The SARS-CoV-2 virus, first detected in India in January 2020, spread rapidly through the country's dense population, overwhelming health systems and causing millions of excess deaths.

The Pandemic in India

• First and second waves: India imposed one of the world's strictest lockdowns in March 2020, with only four hours' notice. The lockdown disrupted livelihoods, triggered a migrant worker crisis, and caused economic devastation, but cases remained relatively low through 2020. The second wave, beginning in March 2021, was catastrophic. The Delta variant spread with terrifying speed, causing oxygen shortages, hospital collapses, and mass cremations. Official death tolls were widely believed to be severe undercounts; epidemiological estimates suggest 3–5 million excess deaths.
• Vaccination campaign: India launched its vaccination program in January 2021, using two locally manufactured vaccines: Covishield (Oxford-AstraZeneca, produced by Serum Institute) and Covaxin (Bharat Biotech). Over 2.2 billion doses were administered, making it one of the largest vaccination campaigns in history. However, the campaign faced challenges: initial supply shortages, digital registration barriers for rural and elderly populations, vaccine hesitancy, and unequal global distribution (India paused vaccine exports during the second wave, affecting the global COVAX program).
• Lessons learned: COVID-19 exposed the chronic underinvestment in India's health system. Oxygen shortages, lack of ICU beds, and the collapse of primary care revealed how decades of neglect had left the system unprepared. At the same time, the pandemic demonstrated the capacity for rapid innovation — from indigenous vaccine development to the CoWIN digital platform — when resources are mobilized. The pandemic also highlighted the importance of social determinants: overcrowding, indoor air quality, comorbidities (diabetes, hypertension, TB), and occupational exposure all shaped vulnerability.

Vector-Borne Diseases: Dengue, Chikungunya, and Japanese Encephalitis

• Dengue: Transmitted by Aedes aegypti mosquitoes, dengue has become endemic in most parts of India. The disease causes high fever, severe body pain ("breakbone fever"), and in severe cases, hemorrhagic fever and shock syndrome. There is no specific treatment, and the vaccine is not yet widely used in India. Dengue outbreaks are seasonal, peaking during and after the monsoon. Urbanization, poor waste management (creating breeding sites), and climate change are expanding dengue's range.
• Chikungunya: Also transmitted by Aedes mosquitoes, chikungunya causes fever and debilitating joint pain that can persist for months or years. Major outbreaks occurred in 2006 and 2016. Like dengue, it is controlled through vector management rather than treatment.
• Japanese Encephalitis (JE): A mosquito-borne viral disease that causes inflammation of the brain, primarily affecting children. JE is endemic in Eastern Uttar Pradesh, Bihar, West Bengal, and Assam. The JE vaccination program, introduced in 2006, has significantly reduced incidence. The 2017 Gorakhpur tragedy — in which over 70 children died at BRD Medical College due to oxygen shortage during a JE outbreak — highlighted the intersection of disease burden and health system failures.
• Lymphatic filariasis: Also known as elephantiasis, this mosquito-borne parasitic disease causes severe swelling of limbs and genitals. India has committed to eliminating lymphatic filariasis by 2027 through mass drug administration (MDA) with diethylcarbamazine and albendazole. Progress has been substantial, but coverage gaps remain.

Eradication Success Stories: Polio and Smallpox

Smallpox Eradication (1975)

India was the last country in the world to eradicate smallpox, declaring itself free of the disease in 1975. The campaign, led by the National Smallpox Eradication Programme (NSEP) with support from WHO, used a strategy of "surveillance and containment" — finding every case and vaccinating everyone in the surrounding area. The final case was detected in a 30-year-old woman in Assam in May 1975. Smallpox remains the only human disease ever eradicated, and India's achievement demonstrated that even in a vast, poor, and densely populated country, eradication was possible.

Polio Eradication (2014)

India was declared polio-free in 2014, after the last case of wild poliovirus was detected in January 2011 in Howrah, West Bengal. This was one of the greatest public health achievements in Indian history. The Pulse Polio Immunization Programme, launched in 1995–96, administered oral polio vaccine (OPV) to over 170 million children during each national immunization day. The program overcame enormous challenges: vaccine hesitancy in Muslim communities (exacerbated by rumors that the vaccine caused sterility), difficult terrain in Uttar Pradesh and Bihar, and the need for repeated doses. The global polio eradication effort continues, with wild poliovirus remaining endemic only in Afghanistan and Pakistan.

National Health Programs

• National Vector Borne Disease Control Program (NVBDCP): Integrates control of malaria, dengue, chikungunya, JE, filariasis, and kala-azar. Provides free diagnosis, treatment, and vector control.
• National Tuberculosis Elimination Program (NTEP): Formerly RNTCP. Provides free diagnosis, DOTS treatment, and DR-TB management through a network of TB units and microscopy centers.
• National AIDS Control Program (NACP) IV: Focuses on prevention, testing, ART, and PPTCT. Operates through State AIDS Control Societies.
• Universal Immunization Program (UIP): Provides free vaccines for 12 diseases (including TB, polio, diphtheria, pertussis, tetanus, hepatitis B, measles, rubella, rotavirus, pneumococcal disease, Japanese encephalitis, and COVID-19). The program reaches approximately 26 million infants and 29 million pregnant women annually.
• National Leprosy Eradication Program (NLEP): India achieved leprosy elimination (prevalence <1 per 10,000) at the national level in 2005, but pockets of high endemicity remain. The program provides multidrug therapy (MDT) free of charge.
• National Viral Hepatitis Control Program (NVHCP): Launched in 2018, focusing on hepatitis B and C — major causes of liver cirrhosis and cancer. Provides free testing and treatment.

Systemic Challenges

• Underfunding: India spends approximately 1.1–1.3% of GDP on health — among the lowest in the world. Public health programs are chronically underfunded, leading to stockouts of medicines, inadequate staffing, and poor infrastructure.
• Human resources: India faces severe shortages of health workers, particularly in rural areas. ASHA workers, who form the backbone of rural health delivery, are volunteers who receive only honorariums, leading to high turnover and low motivation.
• Private sector dominance: The majority of healthcare in India is provided by the private sector, which is largely unregulated. Private practitioners often provide irrational treatment, overprescribe antibiotics, and fail to report notifiable diseases.
• Social determinants: Communicable diseases are fundamentally linked to poverty, malnutrition, sanitation, and housing. Without addressing these underlying determinants, disease control programs can only achieve partial success.
• Antimicrobial resistance (AMR): The irrational use of antibiotics in human medicine and agriculture is driving the emergence of drug-resistant infections. India is one of the world's largest consumers of antibiotics and faces a looming AMR crisis that could undo decades of progress.

Sources